Cointime update: Topline results from the global pivotal Phase III POLARIS-AD trial of AR1001, an oral Alzheimer’s disease drug licensed by Fosun Pharma on a regional basis with exclusive options in core global markets, will be presented for the first time as an oral presentation at the 19th Clinical Trials on Alzheimer’s Disease conference (CTAD 2026) in Boston from November 16 to 19. The data will be disclosed on November 16.
AR1001 Alzheimer’s Phase III Topline Data to Debut at CTAD 2026
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
Xiaomi’s MiMo LLM unit weighs spin-off funding as Lei Jun and Luo Fuli differ
2h ago
Listed Bitcoin Miners Sell Nearly Half Their BTC Reserves to Fund AI Data Centers
4h ago
Nvidia shares rise 3% premarket on stronger-than-expected Q4 revenue forecast
4h ago
Tencent: WorkBuddy Tops 10M Daily Users, 100 Trillion Tokens Consumed
5h ago
HUST and Alibaba Launch Joint AI Security Research Center
5h ago
JPMorgan Keeps Zhipu at Overweight, HK$1,200 Target